RELATED CONTENT
NEWS
- NICE to review Fabre's Javlor again as comparison with unlicensed drugs deemed unfair
- Eisai's Halaven stumbles at NICE efficacy hurdle
- NICE green light helps Merck offer RA patients wider treatment choice
- Familial cholesterol tests from Gen-Probe, Progenika fall short of NICE expectations

